Business Description
Galmed Pharmaceuticals Ltd
SIC : 2834
ISIN : IL0011313900
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 239.59 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 49.9 | |||||
3-Year FCF Growth Rate | 50.8 | |||||
3-Year Book Growth Rate | -55.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 64.97 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -10.69 | |||||
12-1 Month Momentum % | -50.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.48 | |||||
Quick Ratio | 6.48 | |||||
Cash Ratio | 6.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.5 | |||||
Shareholder Yield % | 1.89 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -45.59 | |||||
ROA % | -39.01 | |||||
ROIC % | -177.97 | |||||
3-Year ROIIC % | 661.95 | |||||
ROC (Joel Greenblatt) % | -3542.57 | |||||
ROCE % | -48.37 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.18 | |||||
Price-to-Tangible-Book | 0.18 | |||||
EV-to-EBIT | 1.08 | |||||
EV-to-EBITDA | 1.09 | |||||
EV-to-FCF | 1.14 | |||||
Price-to-Net-Current-Asset-Value | 0.24 | |||||
Price-to-Net-Cash | 0.25 | |||||
Earnings Yield (Greenblatt) % | 92.59 | |||||
FCF Yield % | -100.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 0 | ||
Beta | 0 | ||
Volatility % | 116.06 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0.370714 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | -50.18 | ||
52-Week Range (€) | 3.869999 - 12.524999 | ||
Shares Outstanding (Mil) | 25.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Galmed Pharmaceuticals Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(STU:GPH)'s stock price today?
When is next earnings date of Galmed Pharmaceuticals Ltd(STU:GPH)?
Does Galmed Pharmaceuticals Ltd(STU:GPH) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |